Two small, debt-free Indian companies have emerged as attractive opportunities in the pharmaceutical supply chain. According to reports from The Financial Express, these companies produce pharmaceutical-grade gelatin, a tightly regulated raw material for drug capsules that requires years of certification and audits. The regulatory barriers create a protected moat that keeps new rivals out, with gelatin plants requiring extensive paperwork that cannot be set up overnight. As The Financial Express reports, the specialty chemicals aisle faces challenges from Chinese factories dumping fluorochemicals and agrochemicals at prices local firms cannot match, making this protected niche particularly valuable.
Nitta Gelatin India, incorporated in 1975 and based in Kochi, is the country's largest maker of gelatin, ossein and collagen peptide. As reported by The Financial Express, the company has a market cap of ₹1,562 crore and operates as a joint venture with Kerala State Industrial Development Corporation holding 32% and Osaka-based Nitta Gelatin Inc of Japan holding 43%, giving promoters a 75% grip. The company manufactures gelatin for pharma and food, di-calcium phosphate for poultry feed, and consumer collagen range under the Wellnex brand. According to The Financial Express, Nitta is the biggest player but not alone - India Gelatine and Chemicals, Narmada Gelatines and a few others share the same small pond, with all enjoying a protected pocket due to strict bio-chemical approvals and limited supply of clean animal bone.
According to financial data from The Financial Express, Nitta's net profit compounded at approximately 41% over five years, climbing from ₹18 crore in FY21 to ₹97 crore in FY26. However, sales grew at only 8% annually, reaching ₹588 crore in FY26. The company's operating margin jumped from 11% in FY21 to 23% in FY26, with EBITDA growing at 25% annually over the same period. The company maintains a current ROCE of 27%, nearly double the industry median of 14%. As The Financial Express notes, the share price jumped from around ₹215 in June 2021 to ₹1,720 as of June 25, 2026, representing a 700% increase over five years.
As reported by The Financial Express, Nitta has virtually erased its debt, with borrowings collapsing from ₹80 crore in FY21 to just ₹4 crore, giving a debt-to-equity ratio of 0.01. The company generated strong operating cash flow of ₹122 crore in FY26 and maintains a current dividend yield of 2.2%, significantly higher than the industry median of 0.3%. The company also spent heavily during the year with large investing outflows, pointing to fresh capacity coming up that will weigh on near-term free cash flow even as it sets up future growth.
Narmada Gelatines, incorporated in 1969 and based in Jabalpur, Madhya Pradesh, operates as a true micro-cap with a market cap of ₹286 crore. According to The Financial Express, the company maintains a current dividend yield of 2.2% against an industry median of 0.3%, with the board proposing ₹11 per share for FY26. The company's ROCE stands at approximately 28%, significantly higher than the industry median of 14%, while maintaining borrowings of just ₹8 crore and a debt-to-equity ratio of 0.06. The share price has jumped 155% from ₹185 in June 2021 to ₹473 as of June 25, 2026, though it's currently trading at a 16% discount from its all-time high of ₹566.
